FindTrial
Sign In

Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery

Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06913595
Enrollment
100
Registered
2025-04-06
Start date
2024-03-25
Completion date
2025-11-01
Last updated
2025-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Venous Thrombosis

Brief summary

Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant

Detailed description

This study aims to compare the effectiveness of rivaroxaban versus low molecular weight heparin in reducing the incidence of PMVT after bariatric surgery.

Interventions

DRUGDirect Oral Anticoagulant.

Direct Oral Anticoagulant AFTER BARIATRIC SURGERY

DRUGLow Molecular Weight Heparine

Low molecular weight heparin after bariatric surgery

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

\- BARIATRIC PATIENTS

Exclusion criteria

* BLEEDING TENDENCY

Design outcomes

Primary

MeasureTime frameDescription
VENOUS THROMBOEMBOLISM1 yearDVT after bariatric surgery

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026